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EDITORIAL COMMENT
Estrogen Therapy
for Unstable Angina
Another Bump for the Bandwagon*
David D. Waters, MD, FACC
San Francisco, California
Unstable angina and non-ST-elevation myocardial infarc-
tion (MI) accounted for 1,433,000 hospitalizations in the
U.S. in 1996 (1). Nearly 60% of those with unstable angina
were 65 years and 46% were women. Women comprise a
larger proportion of the unstable angina population than of
the MI population (2).
The outcome of patients with unstable angina has im-
proved remarkably over the past two decades as antiplatelet
therapy, antithrombotic therapy and new revascularization
techniques have been introduced and refined. Nevertheless,
approximately 15% of unstable angina patients will experi-
ence death or nonfatal MI within the first six months.
Reducing this risk represents a major challenge. It could
be argued that further advances in antiplatelet, antithrom-
botic or revascularization treatments are unlikely to re-
ducethis high event rate by more than small increments, and
that new approaches should be tried. For this reason, the
study by Schulman et al. (3) reported in this issue of the
Journal is welcomed.
See page 231
THE CURRENT STUDY
The 293 patients enrolled in this trial exhibited the typical
features of women with unstable angina. Their mean age
was 70 years, more than three-quarters had hypertension,
nearly half had diabetes and one-fifth had had a previous
episode of heart failure. For each of these characteristics, the
prevalence was higher than what would be expected in men
with unstable angina.
The women were randomized to a 30-min intravenous
(IV) infusion of estrogen followed by oral conjugated equine
estrogen for 21 days, IV estrogen followed by conjugated
estrogen plus medroxyprogesterone for 21 days or placebo.
The primary end point, namely ambulatory electrocardio-
graphic ischemic episodes during the first 48 h, was not
reduced by either of the active treatments. In-hospital and
six-month rates of death plus nonfatal MI were also similar
in the three groups.
Study limitations. As noted by the investigators (3), their
study lacked sufficient power to detect modest differences
among the treatment groups. They planned to enroll 351
patients, expected a mean of one ischemic episode per
patient and assumed a 40% reduction in this end point. The
trial was stopped after enrollment of 293 patients because
the mean number of ischemic episodes was only 0.74 per
patient, and the proportion of patients with ischemia had
fallen from 16% in the first third of enrollees to 7.5% in the
last third. An additional reason for stopping was the lack of
any benefit from active treatment.
POTENTIAL EFFECTS OF
ESTROGEN IN ACUTE CORONARY SYNDROMES
The investigators stop short of concluding that hormone
replacement therapy is of no value in the treatment of
unstable angina. Their reticence may stem from the lack
of power of their trial or from the theoretical benefits
that estrogen could confer in unstable angina. Intracoro-
nary 17-estradiol has been shown to potentiate the
acetylcholine-induced increase in coronary blood flow in
postmenopausal women through a nitric oxide–dependent
mechanism (4) and to decrease coronary endothelin-1 levels
(5). In postmenopausal women with coronary disease, either
estrogen or 17-estradiol has been reported to reduce
demand ischemia induced by exercise (6), dobutamine (7) or
atrial pacing (8). These beneficial effects of estrogen might
not be manifest in unstable angina patients who receive IV
nitroglycerin, because it acts through similar mechanisms.
Recurrent events after acute coronary syndromes depend
partly upon the outcome of the struggle between thrombotic
and fibrinolytic forces at the culprit lesion. Oral estrogen,
with or without medroxyprogesterone, but not transdermal
estradiol, enhances fibrinolysis (9). Conversely, oral, but not
transdermal, estradiol shifts markers of coagulation toward
hypercoagulability (10). Estrogen increases blood levels of
matrix metalloproteinase-9, interleukin-6 and C-reactive
protein (11). Matrix metalloproteinases are involved in
plaque disruption, and inflammatory markers reflect an
increased risk of recurrent events. The prothrombotic,
fibrinolytic and pro-inflammatory effects of estrogen may
not be relevant in unstable angina patients receiving anti-
platelet and antithrombotic therapy, just as the vasodilatory
effects may not be relevant in the presence of IV nitroglyc-
erin.
COULD ESTROGEN BE HARMFUL
IN ACUTE CORONARY SYNDROMES?
The stated purpose in this trial (3) was to assess the possible
benefit of estrogen or combined therapy in women with
unstable angina, but of course the potential for harm was
also being assessed. The prothrombotic tendencies of estro-
gen provide a theoretical basis for this concern and data
from recent clinical trials are not reassuring. In the first year
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of treatment in the Heart and Estrogen/progestin Replace-
ment Study (HERS), the incidence of coronary death and
nonfatal MI was higher in the active treatment group:
relative risk (RR) 1.52 (95% confidence interval [CI], 1.01
to 2.29) (12). Women with unstable angina were excluded
from HERS, but the HERS patients were otherwise quite
similar to the women in the current study.
The early increased hazard in HERS was unexpected and
could have been a chance finding. However, a similar trend
has been noted in the Women’s Health Initiative (13). This
trial has randomized 16,609 women either to placebo or to
combined hormone treatment, and 11,739 women who had
had hysterectomies either to placebo or to unopposed
estrogen. The Data and Safety Monitoring Board of this
trial informed participants that “a small increase” in cardio-
vascular events had occurred during the first two years of
treatment in women randomized to active therapy.
In the Coumadin Aspirin Reinfarction Study (CARS),
8,803 patients with recent MI were randomized in a 2  2
factorial design to one of two doses of aspirin and one of two
doses of coumadin. Among the 1,857 postmenopausal
women in CARS, 111 began taking estrogen or estrogen/
progesterone during follow-up (14). The adjusted RR of
death, new MI or unstable angina in these new users was
1.44 (95% CI, 1.05 to 1.99), strikingly similar to the
increased RR in HERS. However, in contrast to HERS, the
excess events were mostly episodes of unstable angina.
Coronary events would not be expected during short-
term treatment periods in small numbers of postmenopausal
women with stable coronary disease. However, 2 of 11
women were withdrawn from one such study when they
developed unstable angina during estrogen/progestin ther-
apy (6). In the context of these findings in previous studies,
the higher frequency of ischemic episodes in women ran-
domized to combination therapy in the present study should
arouse suspicion, even though it is not statistically different
from the frequencies in the other groups.
OTHER ESTROGEN TRIALS
WITH CARDIOVASCULAR END POINTS
In the Estrogen Replacement and Atherosclerosis (ERA)
trial, 309 women with coronary disease were randomized
either to estrogen, estrogen plus medroxyprogesterone or
placebo (15). Coronary arteriography was done at baseline
and after a mean follow-up of 3.2 years, and progression of
coronary atherosclerosis was assessed by quantitative meth-
ods. No differences were found among the three groups for
changes in minimum lumen diameter—the primary end
point—or for any of the other angiographic or clinical end
points.
Two trials have assessed the effects of 17-estradiol on
carotid intimal media thickness. In the Estrogen in the
Prevention of Atherosclerosis Trial (EPAT), 222 post-
menopausal women were randomized to two years of
treatment with either micronized 17-estradiol or to pla-
cebo. Although the results have not yet been published, the
17-estradiol group was reported to have improved carotid
measurements (16). In contrast, the Postmenopausal Hor-
mone Replacement against Atherosclerosis (PHOREA)
trial found no effect of 17-estradiol combined with either
of two doses of a progestin on carotid intimal media
thickness in a study of 321 postmenopausal women followed
for one year (17).
The Papworth HRT and Atherosclerosis Survival En-
quiry (PHASE) included 255 postmenopausal women with
coronary disease, randomized to transdermal 17-estradiol,
with or without cyclic norethisterone (18). The primary end
point, death, MI or hospitalization for unstable angina,
occurred slightly more often in the hormone group (hazard
ratio 1.23, 95% CI, 0.82 to 1.86). The trial was stopped
early because of the likelihood that it would not show
benefit.
Adverse effects of hormone replacement. In both obser-
vational studies (19–21) and clinical trials (22), estrogen use
in postmenopausal women increased the risk of venous
thromboembolic disease. Hormone replacement should be
discontinued in women who are immobilized by fractures,
surgery or stroke. Estrogen replacement increases the risk of
gall bladder disease (23). Use for longer than five years
increases the risk of breast cancer (24).
Unopposed estrogen causes breakthrough bleeding and
endometrial hyperplasia in the older postmenopausal age
group where coronary disease is most prevalent (15), and it
is not practical long-term therapy, even with frequent
monitoring to detect endometrial cancer. Hormone replace-
ment is extremely useful to control menopausal symptoms;
however, older women usually do not appreciate the breast
tenderness and bleeding that often occurs with initiation of
therapy. Even among the selected women who participate in
clinical trials, maintaining compliance with this treatment is
difficult; for example, in HERS the proportion of women
who discontinued hormone treatment was 18% at one year
and 25% at three years (12).
CONCLUSIONS AND CLINICAL IMPLICATIONS
The present study by Schulman et al. (3), and many of the
other studies discussed above, lack sufficient power to be
conclusive. Diehard estrogen advocates will continue to
argue that the problems of hormone replacement relate to
progesterone, or to the type of estrogen, the dose or the
mode of delivery. Future clinical trials may prove that they
are correct. In the meantime, based upon the currently
available information, what are we to do?
The recommendation of the HERS investigators (12),
that hormone replacement therapy not be begun for the
purpose of secondary prevention of coronary disease, is
becoming more widely accepted. Should we go further?
Based upon the suspicion of potential risk, and the docu-
mented absence of any benefit, we should consider discon-
tinuing hormone replacement in women with acute coro-
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nary events, particularly if it had been begun within the
previous year, unless a compelling reason exists to continue
treatment. Many other drugs improve the outcome of
patients after an acute coronary event; thus, we should focus
on compliance with treatment of proven benefit.
In an editorial published in 1996, Jacques Rossouw noted
that two-thirds of physicians reported that they prescribed
hormone replacement therapy for coronary heart disease
despite the absence of conclusive evidence of benefit (25).
Rossouw (25) recommended “putting the brakes on the
bandwagon.” The clinical trial data that have accumulated
since then have vindicated his point of view: the bandwagon
is now bedraggled and the music has died. Yet hormone
replacement is still prescribed by some physicians with the
expectation that it will prevent coronary events. The greatest
advance in our understanding of how estrogen prevents
heart disease may turn out to be our realization that it does
not.
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